Entries by Max

ProBio Trial: Niraparib Plus Abiraterone Shows Greater Clinical Benefit in BRCA-Mutated mCRPC

/in , , /by

New findings from the randomized phase 3  ProBio platform trial suggest that niraparib combined with abiraterone and prednisone may extend clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying homologous recombination repair (HRR) gene alterations, particularly BRCA1/2 mutations. However, no overall survival advantage was demonstrated. The analysis included 99 patients, with 54 receiving […]

Rinzimetostat May Limit Prostate Cancer Lineage Plasticity and Restore Therapeutic Targets

/in /by

New preclinical and translational findings presented at ESMO 2026 suggest that rinzimetostat (ORIC-944), an experimental epigenetic therapy, may help prevent prostate cancer cells from changing their identity to escape androgen receptor (AR)-targeted treatments. Rinzimetostat inhibits the PRC2 complex through its EED subunit. PRC2 regulates gene expression and contributes to lineage plasticity, a process through which […]

Newsletter 43/2026

/in /by

  LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! New findings from the ESMO 2026 meeting are starting to come in, and there’s plenty to talk about. So grab yourself something to drink, get comfortable, and enjoy! Stay strong and fight on! As usual, we […]

Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer

/in , , /by

The phase 3 DASL-HiCaP trial, presented at ESMO 2026, has demonstrated improved metastasis-free survival with the addition of darolutamide to androgen deprivation therapy (ADT) and radiotherapy in patients with localised or locally advanced prostate cancer at high risk of recurrence. The randomised, placebo-controlled study enrolled 1,106 patients, who received darolutamide or placebo alongside ADT and […]

UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide

/in , , /by

New results from a randomised substudy of the phase 3 PROTEUS trial, presented at ESMO 2026, show that adding apalutamide and androgen deprivation therapy (ADT) before and after radical prostatectomy improves outcomes compared with surgery alone in patients with high-risk localised or locally advanced prostate cancer. The substudy enrolled 408 patients, including 102 receiving perioperative […]

UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations

/in , , , /by

New phase 1/2 results published in the Journal of Clinical Oncology provide further evidence of the clinical activity of bavdegalutamide (ARV-110), an experimental androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings suggest that specific AR mutations may help identify patients most likely to benefit from this treatment. Unlike conventional […]

UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001

/in , , , /by

Updated results from the TheraPb phase 1 trial, presented at ESMO 2026, provide longer-term follow-up for ²¹²Pb-ADVC001, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 22 heavily pretreated patients across different dose levels and treatment schedules. With an additional 12 months of observation and a median follow-up of […]

PEACE-1: Triplet Therapy Shows Lasting Survival Benefit at Eight Years

/in , , /by

After a median follow-up of 7.7 years, the phase 3 PEACE-1 trial confirms a lasting survival benefit from adding abiraterone and prednisone to standard treatment for men diagnosed with metastatic hormone-sensitive prostate cancer. The trial enrolled 1,173 men and tested the addition of abiraterone, prostate radiotherapy, or both to androgen deprivation therapy (ADT), with or […]

UPDATE: JNJ-6143 Shows Early Activity in Advanced Prostate Cancer

/in , , /by

Updated phase 1 results provide further evidence of activity for JNJ-6143, previously known as HLD-0915 and also referred to as JNJ-101556143, in heavily pretreated metastatic castration-resistant prostate cancer. Following our previous coverage of its initial results and a separate phase 2 trial, the new findings add dose-specific outcomes and exploratory molecular data. JNJ-6143 is an […]

Phase 1 ProTACT: Actinium-225 FL-020 Shows Early Activity in Advanced Prostate Cancer

/in , , /by

New results show preliminary antitumor activity for 225Ac-FL-020, an investigational PSMA-targeted alpha radioligand, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from ProTACT, an ongoing first-in-human phase 1 trial evaluating the safety, dosing, and preliminary efficacy of FL-020 in patients previously treated with androgen receptor pathway inhibitors and taxane chemotherapy, unless chemotherapy […]